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ABSTRACT
Context: Oleanolic and ursolic acids are antitumor and antibacterial agents which are extensively studied.
Their major disadvantage is the poor water solubility which limits their applications.
Objectives: Oleanolic and ursolic acid were encapsulated into polyurethane nanostructures that act as
drug carriers. In order to evaluate the effectiveness of the particles, anti-microbial and anti-proliferative
activity compared to un-encapsulated active compounds was tested.
Materials and methods: Using an interfacial polycondensation technique, combined with spontaneous
emulsification, structures with nanoscale dimensions were obtained. Scanning electron microscopy, differ-
ential scanning calorimetry and X-ray assays confirmed the encapsulation process. Concentrations of 10
and 30lM particles and un-encapsulated compounds were tested by MTT viability assay for several breast
cancer lines, with an exposure time of 72 h. For the antibacterial studies, the dilution method with MIC
determination was used.
Results: Ursolic acid had an excellent inhibitory effect with IC50 value of 2.47, 1.20, 1.26 and 1.34lM on
MCF7, T47D, MDA-MB-231 and MDA-MB-361, respectively. Oleanolic acid did not show anti-proliferative
activity. The pure compounds showed their antibacterial activity only against Bacillus species and Candida
albicans, but MIC values were too high to be considered efficient antimicrobial agents (2280 and 4570lg
mL 1, respectively). Polyurethane nanoparticles which incorporated the agents did not show any
biological activity.
Discussion and conclusion: Although the active compounds did not fully exert their anti-proliferative
activity following encapsulation inside polymeric nanoparticles, in vivo evaluation is needed in order to
obtain an exhaustive conclusion, as the active compounds could be released as a result of metabolic
activity.
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Introduction
Breast cancer is one of the most common cancers worldwide,
being the second leading cause of cancer related death, after lung
cancer, in the USA. Further, it is the most common women
malignancies (Wang et al. 2012). In spite of major research,
efforts in developing new therapeutic modalities, effective cure of
locally advanced or metastatic cancers remains an unmet goal in
oncology. Also, many chemotherapy and targeted drugs, and
combinations of the two, have substantial systemic toxicity which
often limits their administration (Workman 2001). Much atten-
tion is now devoted to cancer prevention and early detection and
to the development of less toxic treatments. In this context, new
classes of compounds are being explored, in particular, plant-
derived molecules, including pentacyclic triterpenes. Triterpenes
are compounds widely-spread in plants and an integral part of
commonly consumed foods. Pentacyclic triterpenes consist of a
30-carbon skeleton formed by the cyclization of squalene
(Gayathri et al. 2010; George et al. 2012) exhibiting mainly anti-
proliferative properties (Dehelean et al. 2011, 2012). Oleanolic
acid (OA) (3b-hydroxy-olean-12-en-28-oic acid) and its isomer
ursolic acid (UA) (3b-hydroxy-urs-12-en-28-oic acid) are triterpe-
noids (Feng et al. 2009) with pharmacological activity ranging
from antitumor, antiviral, anti-inflammatory, hepatoprotective,
antidiabetic and gastro-protective activities (Sun et al. 2006;
Prasad et al. 2012). Although antitumor activities of OA and UA
were reported in cancers (breast, liver, prostate), melanoma, leu-
kemia and lymphomas, both in vitro and in vivo (Sun et al. 2006;
Yim et al. 2006; Zhang et al. 2007), their mechanisms of action
remain largely elusive.
Recently, these pentacyclic triterpenes have been studied for
their antibacterial activity, as well as for their potential to enhance
the susceptibility of bacteria to antibiotics (Kurek et al. 2012; do
Nascimento et al. 2013), bacterial resistance remains a serious
challenge of the 21st century (Fontanay et al. 2008; Mokoka et al.
2013). UA and OA have also showed antimicrobial and antifungal
activity, in some cases even on methicillin- or vancomycin-resist-
ant strains (Horiuchi et al. 2007; Kim et al. 2012).
Bioavailability of these compounds is limited by low water
solubility leading to low efficiency, which is worsened by its non-
specific distribution in the body (Lopes et al. 2013; Zhang et al.
2013). In the last decade, nanotechnology has provided possible
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solutions to the bioavailability limitations of active substances,
limitations which influence the effectiveness of the active com-
pounds in therapy (Lopes et al. 2013).
The aim of this study was the synthesis of a polyurethane drug
delivery system with oleanolic and ursolic acids incorporated as
active drugs and the determination of their anti-proliferative
activity on breast cancer cell lines as well as their antibacterial
activity against several bacterial strains.
Materials and methods
Substances
UA and OA of analytical purity were purchased from Fluka
(Sigma Aldrich, Steinheim, Germany). The chemicals were pur-
chased as follows: ethylene glycol (EG) from Lach-Ners.r.o.
(Czech R.), 1,4-butanediol (BD) from Carl Roth GmbH
(Germany). Polyethylene glycol M¼ 200 (PEG), the solvent (acet-
one), isophorone diisocyanate (IPDI) and surfactants (SpanVR 85
and TweenVR 20) were purchased from Merck (Germany). All sub-
stances and reagents were used as received.
Synthesis of polyurethane drug delivery system
Polyurethane particles were synthesized as described in literature
(Bouchemal et al. 2004), using a multi-step procedure based on
the interfacial polycondensation technique combined with spon-
taneous emulsification. The organic phase (1.5mL IPDI, 1.5mL
SpanVR 85, mixed with 15mL acetone and heated at 30 C) was
injected into the aqueous phase (0.8mL EG, 0.8mL BD, 0.3mL
PEG and 1.5mL TweenVR 20 mixed with 15mL distilled water and
heated at 30 C). The injection of organic phase into the aqueous
phase was made under magnetic stirring (500 rpm) and heated
(40 C) for 4 h in order to ensure the completion of the chemical
reaction. The products were repeatedly washed with a mixture
acetone/water (1:2, v/v). After synthesis, the obtained particles
were maintained as thin layers (around 3mm thickness) in Petri
dishes at 80 C in an oven for 12 h, for acetone and water
removal. Oleanolic and ursolic acids were separately added (in
organic phase) in two experiments while in the third one empty
polymeric nanoparticles were used as control.
Nanoparticle size distribution
The size distribution of the obtained polyurethane nanoparticles
was measured using a particle size analyzer (Vasco from
Cordouan Tech., Pessac, France). Solutions of 1:100 (w/w) in
ethanol were prepared. The parameters used were as follows:
25 C temperature, 190 channels, 80% laser power, 18 ls time
interval, continuous acquisition mode and Log-normal dispersion.
Three measurements were done for each sample and an average
value was considered.
Differential scanning calorimetry (DSC)
Heating behavior was assessed by differential scanning calorimetry
(DSC), measuring the heat energy that occurs with phase changes
in the sample when subjected to temperature change.
Measurements were made using a Mettler Toledo STAR Thermal
Analysis System, DSC 821 (Mettler Inc., Schwerzenbach,
Switzerland). Argon was used as carrier gas at a flow rate of 10 L
h 1 during the DSC investigation. Approximately 2–5mg of
ursolic acid, oleanolic acid and their nanoparticles were examined
in a temperature range from 25 to 350 C with a heating rate of
5 C/min.
X-ray diffraction
A Philips PW 1710 diffractometer (PW 1930 generator, PW 1820
goniometer, Angstrom Advanced Inc., Braintree, MA) was used to
obtain the X-ray-diffraction patterns. The tube anode was Cu
with Ka¼ 1.54242Å. The pattern was collected with a tube volt-
age of 50 kV and 40mA of tube current in step scan mode (step
size 0.035, counting time 1 s per step).
Scanning electron microscopy (SEM) assay
The shape and crystal morphology of the particles were measured
using scanning electron microscopy (SEM) (Hitachi S4700,
Hitachi Scientific Ltd., Hitachi, Japan) as described in the litera-
ture (Soica et al. 2012). Electric conductivity on the surface of the
samples was induced by a sputter coating apparatus (Bio-Rad SC
502, VG Microtech, Uckfield, UK). The air pressure was
1.3–13.0mPa. The samples were fixed onto a metallic stub with
double-sided conductive tape (diameter 12mm, Oxon, Oxford
Instruments, Abington, UK). Images were taken in secondary
electron image mode at 10 kV acceleration voltages.
Particle cellular uptake studies
Nanoparticle internalization studies were performed using a fluor-
escent marker, as described in the literature (Zhang et al. 2013).
Coumarin-6 loaded nanoparticles (12.5 lg mL 1) were prepared
using the interfacial polycondensation technique combined with
spontaneous emulsification as described in the above section.
5 104 MCF-7 cells were seeded into 24-well plates and incubated
overnight in 5% CO2 atmosphere at 37 C. After 24 h, the
medium was replaced with a new medium containing coumarin-6
loaded nanoparticles and cells were incubated for 24 and 48 h,
respectively. After the incubation period, the medium was
removed and cells were rinsed with a new medium. Fluorescence
microscopy (Nikon Eclipse TE300, Amstelveen, The Netherlands)
with FITC/DAPI/Hoechst filters was used to observe the efficiency
of coumarin-6 loaded nanoparticles internalization in cells. After
48 h of exposure, cell nuclei were counterstained with Hoechst
dye (5min incubation in the dark, followed by supernatant
removal and microscope visualization).
In vitro antibacterial activity
Oleanolic acid, ursolic acid and their polyurethane structures were
tested for their antimicrobial activity against six bacterial strains:
Staphylococcus aureus (ATCC25923), Escherichia coli
(ATCC25922), Pseudomonas aeruginosa (ATCC27853),
Salmonella enteritidis (D) (ATCC 13076), Bacillus subtilis (6633),
Bacillus cereus (14579); and Candida albicans (ATCC10231) by
the dilution method with MIC (minimal inhibitory concentration)
determination. All the bacterial strains used were prepared from
24 h old cultures. Suspensions were adjusted to a McFarland’s
standard of 0.5 (a final bacterial concentration of 1–2 108
CFUmL 1). The final dilution was 1:200 bacteria in Muller-
Hinton broth (Sanimed, Romania, Bucharest), which was incu-
bated at 37 C. This resulted in approximately 5 105
CFUmL 1. In glass test tubes, a 200lL bacterial suspension was
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distributed to 200 lL of test medium containing the tested sub-
stances. These tubes were incubated for 18 h at 37 C. The initial
solutions of ursolic and oleanolic acids and their nanoparticles
were obtained by dissolving the substances in 1 mL of dimethyl
sulfoxide (DMSO) to obtain an initial concentration of 4.56mg
mL 1. From this concentration, serial dilutions were made in dis-
tilled water in order to reach final concentrations in the range of
290–4570 lg mL 1. The minimum concentration of the com-
pound which inhibited the visible growth of the tested micro-
organism (MIC) was recorded. Since the stock solutions were
prepared in DMSO, 20lL of the solvent were introduced in a
tube with 200 lL bacterial suspension and 180 lL nutrient
medium, being used as negative control. As positive control for
antimicrobial activity and Candida albicans, gentamicin and flu-
conazole were used. Triplicate tests were performed for all
samples.
Cell culturing and anti-proliferative assay
Anti-proliferative assays were performed as described in literature
(Soica et al. 2014). Four human breast cancer cell lines (MCF7,
MDA-MB-231, MDA-MB-361 and T47D) were purchased from
European Collection of Cell Cultures (Salisbury, UK). All the
chemicals used for cell culturing, unless otherwise specified, were
purchased from Sigma-Aldrich Ltd. (Budapest, Hungary). Cells
were grown in minimal essential medium supplemented with 10%
fetal bovine serum (FBS), 1% non-essential amino-acids and an
antibiotic-antimycotic mixture in a humidified atmosphere of 5%
CO2 at 37 C. 5000 cells/well were seeded onto 96-well plates and
allowed to attach overnight. After 24 h, the medium containing
the tested compounds was added and cells were incubated for
72 h. The tested concentrations were 10 and 30 lM. After the
incubation time, when active substances exerted their action, via-
bility was determined by the addition of 20 lL of [3-(4, 5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (5mg
mL 1) (Mosmann 1983). The precipitated formazan crystals were
solubilized in DMSO and the absorbance was read with an ELISA
reader at 545 nm. Cisplatin, a clinically utilized anticancer agent,
was used as positive control on the cell lines. It exerted growth
inhibition values of 66.9% and 96.8% (MCF7), 51.0% and 57.9%
(T47D), 20.8% and 71.7% (MDA-MB-231), 67.5% and 87.7%
(MDA-MB-361) at 10 and 30 lM, respectively.
In order to establish the IC50 values for ursolic acid, concentra-
tions between 0.3 and 10lM were tested.
Statistical analyses (One-Way ANOVA followed by Newman-
Keuls post test) and calculations were performed by means of
GraphPad Prism 4.0 (GraphPad Software; San Diego, CA, USA).
All measurements were performed in triplicate and data were pre-
sented as mean ± standard deviation.
Results
Nanoparticles size distribution
Polyurethane nanoparticles containing the tested compounds were
synthesized by using the interfacial polyaddition procedure com-
bined with spontaneous emulsification. Figure 1 presents the
results of the particle size distribution for the polyurethane nano-
particles incorporating OA (OAþPU), polyurethane nanopar-
ticles incorporating UA (UAþPU) and empty polyurethane
nanoparticles (PU). Nanoparticles size distributions were as fol-
lows: for OAþ PU Dv50: 48.99 nm and Dv 90: 77.65 nm; for
UAþ PU Dv50: 9.77 nm and Dv90: 26.92 nm; for PU Dv 50:
18.63 nm and Dv90: 371.63 nm. For PU containing OA and UA
samples only one particle population was obtained, which indi-
cates that homogeneous samples were prepared. For PU sample, a
second population was observed, which could be the result of
nanoparticle agglomeration (Bouchemal et al. 2004). Several bene-
fits of nanoparticles were described by Bouchemal et al. (2004),
one of them being the enormous surface area which makes them
suitable for pharmaceutical applications such as lipophilic encap-
sulated drugs for homogeneous release.
Scanning electron microscopy (SEM) assay
The morphology of the active substances of the polyurethane used
for encapsulation and of the encapsulated compounds was
obtained by SEM. The results are shown in Figure 2. The crystal-
line structures of ursolic acid (Figure 2(c)) and the amorphous
structure of oleanolic acid (Figure 2(a)) can be noticed. Figures
2(b) and (d) exhibit a film, similar to Figure 2(e) (empty polyure-
thanic nanostructures), which leads us to the conclusion that the
encapsulation process took place.
Differential scanning calorimetry (DSC)
Thermal behaviors of OA (a), PUs (b) and OAþ PU (c) are
depicted in Figure 3.1. In case of pure OA, loss of water is indi-
cated by the endothermic peak at 117.29 C. The melting point
for OA is around 315 C (Liu & Wang, 2007) and it was not
observed within the temperature range of this study (25–300 C).
For the PU, no peak was observed in the range of study. The
OAþ PU revealed a similar curve as the empty structures, indi-
cating the encapsulation of the active substance. Encapsulation of
OA into the polyurethane vehicle does not change the melting
point of the pure OA (no peak was observed under 300 C).
Thermal behaviors of pure UA, UAþ PU and PU are depicted
in Figure 3.2. For UA, an endothermic peak was observed at
280.63 C, indicating the melting point of the compound. The
curves for PU and UAþ PU display a similar profile. Moreover,
these nanoparticles showed a heating behavior quite similar to the
one presented in Figure 3.1, for the OAþPU. Altogether, data
could lead to the conclusion that the encapsulation process of the
active substances took place.
X-ray diffraction
Used to characterize changes in the crystalline structure of com-
pounds after molecular interactions (Soica et al. 2014), X-ray dif-
fraction analysis was used to assess the crystalline structure of UA
(Figure 4.2(a)) and OA (Figure 4.1(a)). As shown in Figure 4.1a
and 4.2a, crystalline compounds are characterized by sharp peaks,
UA displaying a higher degree of crystallinity than OA. For the
PU (Figure 4.1(b); 4.2(b)) and for the OAþ PU (Figure 4.1(c))
and UAþPU (Figure 4.2(c)), the X-ray profile exhibits indistin-
guishable peaks, revealing the amorphous nature of the com-
pounds. These changes in the crystalline state of the substances
also act as indicators of the encapsulation process.
Particle cellular uptake studies
Figure 5 shows the microscopic images of MCF-7 cells treated
with coumarin-6 loaded nanoparticles after 24 h (a) and 48 h (b)
of incubation. As shown in Figure 5, nanoparticles uptake in the
cells was a time-dependent process. At the 24 h exposure
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Figure 2. Scanning electron microscopy (SEM) pictures for: (a) oleanolic acid (OA); (b) polyurethane nanostructures containing oleanolic acid (OAþ PU); (c) ursolic acid
(UA); (d) polyurethane nanostructures containing ursolic acid (UAþ PU); (e) empty polyurethane nanostructures (PU).
Figure 1. Distribution of polyurethane structures for: polyurethane nanoparticles containing oleanolic acid (OAþ PU), polyurethane nanoparticles containing ursolic acid
(UAþ PU) and empty polyurethane nanoparticles (PU). Parameters used were: 25 C, 190 channels, 80% laser power, 18 ls time interval, continuous acquisition mode
and Log-normal dispersion.
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timepoint, the coumarin-6 loaded nanoparticles were localized
mostly onto the cellular membrane (Figure 5a). After 48 h of
exposure, nanoparticles were localized around the cells nuclei and
inside the cytoplasm (Figure 5b). As reported by Zhang et al.
(2013) and others (Rosen & Abribat 2005), cellular uptake of
nanoparticles is an important factor which influences the effi-
ciency of therapeutic effects.
Anti-proliferative activity
Figures 6 and 7 show the growth inhibition percent of the breast
cancer cell lines after treatment with OA and UA, respectively.
Also, the results of inhibition after exposure to the two com-
pounds incorporated into PU are presented.
One can notice (Figure 6) that OA has a poor cytotoxic activ-
ity on the three cancer cell lines at the tested concentrations.
Concentration of 10 lM of pure OA inhibited only 2.92 ± 5.39%
of the MCF-7 cells while for the T47D human ductal breast epi-
thelial tumor cell line and the MDA-MB-231 human breast car-
cinoma the inhibition index was 16.11 ± 5.16% and 5.71 ± 2.75%,
respectively. Increasing the concentration to 30 lM, an inhibition
of 5.98 ± 5.56%, 15.54 ± 6.14% and 11.92 ± 3.44% for the MCF-7,
T47D and MDA-MB-231, respectively, was detected.
Incorporation of OA inside the PU proved to increase very poorly
the inhibition percent on all three cell lines, in both concentra-
tions. Results are as follows: (i) for MCF7 cell line: 1.28 ± 4.55%
for 10 lM OA, 8.07 ± 3.28% for 30 lM OA; (ii) for T47D cell
line: 7.23 ± 1.28% for 10 lM OA, 20.15 ± 3.24% for 30 lM OA;
(iii) for MDA-MB-231 cell line: 10.25 ± 5.56% for 10 lM OA and
17.73 ± 4.95% for 30 lM OA. The polyurethane nanoparticles pro-
duced the following inhibition values: (i) for MCF-7 cell line,
3.24 ± 3.47% and 0.74 ± 2.74% for 10 and 30 lM, respectively;
(ii) for T47D, 12.56 ± 4.23% and 24.95 ± 3.10% for 10 and 30 lM,
respectively; and (iii) for MDA-MB-231 cells, 5.80 ± 1.50% and
13.63 ± 4.30% for 10 and 30 lM, respectively.
In contrast, pure UA (Figure 7) proved to be very active on all
three breast cancer lines even at the lowest concentration.
Additionally, the PU and UAþPU were also tested on MDA-
MD-361 cell lines. For all tested cell lines, the inhibition was
more than 90% for both concentrations (10 and 30 lM). Results
are as follows: (i) on MCF7 cell line: 93.86 ± 0.72% for 10lM UA
and 93.70 ± 0.46% for 30 lM UA; (ii) on T47D cell line:
95.38 ± 0.79% for 10 lM UA and 95.83 ± 0.78% for 30 lM UA;
(iii) on MDA-MB-231 cell line: 95.87 ± 1.04% for 10lM UA and
95.21 ± 1.11% for 30 lM UA; (iv) on MDA-MB-361 cell line:
91.66 ± 1.82% for 10 lM UA and 91.07 ± 1.70% for 30 lM UA.
The growth inhibition results for the UAþPU are as follows: (i)
-3.67 ± 2.07%, 22.29 ± 3.73%, 0.48 ± 3.09% and 1.11 ± 6.05% for
MCF7, T47D, MDA-MB-231 and MDA-MB-361 cell line, respect-
ively, for the concentration of 10 lM UA and (ii): 2.96 ± 1.45%,
33.58 ± 1.56%, 12.30 ± 4.45%, 11.19 ± 5.61% for MCF7, T47D,
MDA-MB-231 and MDA-MB-361 cell line, respectively, for the
concentration of 30 lM UA. In order to calculate the IC50 values
Figure 4. X-ray diffractograms of: (a) oleanolic acid (OA) (4.1) and ursolic acid (UA) (4.2), (b) empty polyurethane nanostructures (PU) (4.1; 4.2), (c) polyurethane nano-
structures containing oleanolic acid (OAþ PU) (4.1) and ursolic acid (UA) (4.2). The measurements were conducted with a 50 kV tube voltage and tube current of 40mA
in step scan mode (step size 0.035, counting time 1 s per step).
Figure 3. Differential scanning calorimetry (DSC) curves of: (a) oleanolic acid (OA) (3.1) and ursolic acid (UA) (3.2), (b) empty polyurethane nanostructures (PU) (3.1; 3.2),
(c) polyurethane nanostructures containing oleanolic acid (OAþ PU) (3.1) and ursolic acid (UAþ PU) (3.2). Argon was used as carrier gas, the temperature range was
between 25 up and 300 C, and the heating rate was 5 C min 1, while the sample weight was 2–5mg.
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Figure 5. Microscopic images of MCF-7 human breast cancer cells incubated with coumarin-6 loaded nanoparticles after (a) 24 h and (b) 48 h.
Figure 6. Inhibition of MCF7, T47D and MDA-MB-231 breast cancer cell lines after 72 h exposure on 10 and 30lM of oleanolic acid (OA), empty polyurethane nanostruc-
tures (PU) and polyurethane nanostructures containing oleanolic acid (OAþ PU).
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for UA, concentrations between 0.3-10 lM were tested. The calcu-
lated IC50 values were as follows: 2.47, 1.20, 1.26 and 1.34 lM for
MCF7, T47D, MDA-MB-231 and MDA-MB-361, respectively.
In vitro antibacterial activity
The in vitro antibacterial activity of triterpenic acids and their for-
mulations has been tested on several bacterial strains, Gram-posi-
tive and negative, as well as the fungal species, C. albicans. OA
and UA exhibited antibacterial activity only against Bacillus cereus
and Bacillus subtilis strains. The MIC values were 4570 lgmL 1
in case of the Bacillus cereus, for both acids, while for Bacillus
subtilis the MIC values were 2280 and 4570lgmL 1 for OA and
UA, respectively. Our study revealed a lack of antimicrobial activ-
ity of all samples against the tested strains of Gram-negative bac-
teria. A loss of in vitro antibacterial activity was reported when
tested substances were encapsulated into the PUs. Also, both UA
and OA showed a poor antifungal activity on Candida albicans,
with MIC values of 4570 lg mL 1. In terms of antifungal activity
when polyurethane nanoparticles were assessed, only those con-
taining oleanolic acid were active against Candida albicans.
Discussion
The antitumor potential of the OA and UA is already well known.
Researchers have widely studied this activity on different types of
cancer, both in vitro and in vivo. The two compounds have simi-
lar chemical structures and therefore similar pharmacological
activities, often being studied together (Feng et al. 2009;
Chakravarti et al. 2012); also, they are often found together as
components of some plants (Feng et al. 2009). However, their
antitumor activity is different depending on the cancer cell lines
used as well as on potency, in some cases UA proving to be more
effective than OA (Liu 1995; Feng et al. 2009).
Chakravarti et al. (2012) studied the anticancer activity of OA
and UA as an equimolar mixture extracted from leaves of
Wrightia tomentosa Roem. & Schult. (Apocynaceae), on MCF-7
and MDA-MB-231 cell lines and concluded that the anti-prolif-
erative effect was due to the induction of apoptosis by extrinsic
and intrinsic apoptosis pathways after exposure to the mixture.
Shan et al. (2011) reported UA and OA cytotoxic effects against
MCF-7/wt cells and adriamycin resistant breast cancer cell line
MCF-7/ADR with IC50 of 30 and 40lM UA, respectively. Our
study on MCF-7 shows that after 72 h, even small concentrations
such as 10lM UA inhibited more than 90% of the breast cancer
cells; similar results were obtained on MDA-MB-231 and T47D
cell lines. Shan et al. (2011) also reported cytotoxic effects for OA
with IC50 values of 28 and 44 lM on MCF-7/wt and MCF-7/
ADR, respectively. Contrary to their results, our study reveals that
10 and 30lM OA failed to inhibit the viability of human breast
cancer MCF-7 cells. Moreover, MDA-MB-231 and T47D cell lines
appeared to be resistant to the OA treatment. These findings are
consistent with other studies that reported a weak cytotoxic activ-
ity of OA on both MCF-7 and MDA-MB-231 cells (Hsu et al.
2005; Bishayee et al. 2011). The encapsulation of UA into the PU
led to poor in vitro results, the growth inhibition significantly
decreasing for all cell lines when compared to pure UA. Except
for the MCF-7 cell line, the empty polyurethane nanoparticle
proved to have an antiproliferative activity of up to 25%. Based
on other researchers’ results that the association of two com-
pounds with antitumor activity would lead to a synergism of
action (Chen et al. 2010; Trandafirescu et al. 2014), we assumed
that encapsulation on the active compounds into nanoparticles
with own inhibitory activity could result in a potentiation of the
inhibitory activity. With respect to the synergistic concept, our
Figure 7. Inhibition of MCF7, T47D and MDA-MB-231 breast cancer cell lines after 72 h exposure on 10 and 30lM of ursolic acid (UA), empty polyurethane nanostruc-
tures (PU) and polyurethane nanostructures containing ursolic acid (UAþ PU).
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previous studies on ursolic and oleanolic acids formulated as
inclusion complexes with cyclodextrins showed a synergistic activ-
ity of the active compound and the hydrophilic cyclodextrin
which served as a host-molecule for the triterpenic compound
(Soica et al. 2014). Contrary to our presuppositions, the encapsu-
lation of ursolic acid into the polyurethane nanoparticles led to
poor in vitro results, the growth inhibition significantly decreasing
for all cell lines when compared to pure ursolic acid. Regarding
the encapsulation of oleanolic acid into poliurethane nanoparticles
no improvement of in vitro anti-proliferative activity was
observed.
In terms of antibacterial activity, other studies reported the
activity of these pentacyclic triterpenes extracts isolated from
medicinal plants. However, many reports are contradictory, other
researchers obtaining negative results against the same bacterial
strains. Fontanay et al. (2008) reported positive results while using
UA and OA against Gram-positive bacteria combined with a lack
of activity against Gram-negative bacteria. Although our results
confirm the activity of these compounds against Bacillus subtilis
and Bacillus cereus, both Gram-positive bacteria, the MIC values
were so high compared with gentamicine (the standard reference
against Bacillus species, whose MIC is 0.06 lgmL1) that the
efficacy of the two compounds against the tested strains of
Bacillus species is questionable. In contrast, do Nascimento et al.
(2013) reported UA activity against Gram-negative bacteria. A
possible explanation for these contradicting results could be that
most studies dealt with antibacterial activity of total plant extracts.
After establishing the chemical composition of the extracts, the
respective reported activity was attributed to different compounds
identified in the extract (Horiuchi et al. 2007). An interesting
hypothesis is that the antibacterial activity might be a result of
synergism between different herbal components (Fontanay et al.
2008). In terms of triterpenes’ activity against Candida albicans,
antifungal effects were reported by Shai et al. (2008) for UA iso-
lated from Curtisia dentata (Burm. F) C.A. Sm. leaves
(Cornaceae). As already emphasized, the present paper shows
similar antibacterial spectra for both pure UA and OA, but not
for the OAþ PU and UAþPU, positive results being reported
only for OAþ PU at a very high concentration.
Based on previous reports that transmembrane transport
vehicles could improve the bioavailability of active compounds
(Chen et al. 2011; Gao et al. 2012; Zhang et al. 2013), we con-
ducted in vitro antitumor and antibacterial tests on PUs contain-
ing the two triterpenic acids. Results showed that both active
agents were not able to fully exert their pharmacological activity
in vitro following encapsulation inside PUs. In vitro tests are
important preliminary tools, providing significant information in
terms of biological effects; however, in vivo investigations are
necessary, given the fact that active substances could be released
in vivo, following metabolic activity.
Conclusions
Altogether, the paper discusses the in vitro anti-proliferative
potential of UA on breast cancer cell lines as well as the lack of
activity for OA at the same concentrations, in vitro antibacterial
studies show poor antimicrobial activity of the compounds against
Bacillus species, a Gram-positive bacterial strain, and antifungal
activity against Candida albicans, at high doses. Although poor in
vitro preliminary results are reported for the polyurethane nano-
particles as carriers for the active compounds, in vivo evaluations
are needed in order to evaluate the possibility of releasing the
active compounds as a result of metabolic activity.
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